ADA InVivo B.V. offers a new technology for predicting human patients’ immune responses to protein-based therapeutic drugs: In vivo immunogenicity testing using genetically modified mice. Predicting immunogenicity in an early stage of protein drug development can save the pharmaceutical industry large amounts of investment dollars and reduce time-to-market of new medicines. Additionally, ADA InVivo B.V. leverages its quality control expertise (GLP, ISO) by offering Quality Management Control, Auditing & Certification services across a range of industries, including Medical and Automotive.